Janakiraman Subramanian

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Epidermal Growth Factor Receptor

Top Venues

Expert opinion on pharmacotherapy

Expert review of anticancer therapy

Translational lung cancer research

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Nagla Abdel Karim, Mohamed Zaza, Janakiraman Subramanian
Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development-are we close to the finish line? Translational lung cancer research 13 (8) (2024)
Ritu Jain, Janakiraman Subramanian, Anurag Singh Rathore
A review of therapeutic failures in late-stage clinical trials. Expert opinion on pharmacotherapy 24 (3) (2022)
Ritu Jain, Janakiraman Subramanian, Anurag Singh Rathore
A review of therapeutic failures in late-stage clinical trials. Expert opinion on pharmacotherapy (2022)
Lara Kujtan, Rama Krishna Kancha, Beth Gustafson, Lindsey Douglass, Christopher Rh Ward, Blake Buzard, Janakiraman Subramanian
Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. Expert review of anticancer therapy 22 (2) (2022)
Ritu Jain, Janakiraman Subramanian, Anurag Singh Rathore
A review of therapeutic failures in late-stage clinical trials. Expert opinion on pharmacotherapy 24 (3) (2022)
Ritu Jain, Janakiraman Subramanian, Anurag Singh Rathore
A review of therapeutic failures in late-stage clinical trials. Expert opinion on pharmacotherapy (2022)
Janakiraman Subramanian, Ossama Tawfik
Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective. Expert review of anticancer therapy 21 (8) (2021)
Lara Kujtan, Janakiraman Subramanian
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert review of anticancer therapy 19 (7) (2019)
Janakiraman Subramanian, Archana Katta, Ashiq Masood, Dashavantha Reddy Vudem, Rama Krishna Kancha
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers. The oncologist 24 (12) (2019)
Zaheer Ahmed, Lara Kujtan, Kevin Kennedy, Valerie Wood, David Schomas, Janakiraman Subramanian
The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database. Cancer medicine 8 (4) (2019)